


REPORT DOCUMENTATION PAGE

AD-A231 814

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|-------------------------------------|--|---|--|----------------------------------|---------------|--|------------|-------------------------------------|----------|--------------------------|-------------|--------------------------|---------------|--|----------|--|---------------|--|--------------------|--|------|----------------------|-----|----|
| 1a. REPORT SECURITY CLASSIFICATION Unclassified | | | 1b. RESTRICTED | | | | | | | | | | | | | | | | | | | | | | |
| 2a. SECURITY CLASSIFICATION AUTHORITY | | | 3. DISTRIBUTION STATEMENT OF REPORT Approved for public release; distribution unlimited | | | | | | | | | | | | | | | | | | | | | | |
| 2b. DECLASSIFICATION/DOWNGRADING SCHEDULE | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4. PERFORMING ORGANIZATION REPORT NUMBER(S) | | | 5. MONITORING ORGANIZATION REPORT NUMBER(S) | | | | | | | | | | | | | | | | | | | | | | |
| 6a. NAME OF PERFORMING ORGANIZATION Utah State University | | 6b. OFFICE SYMBOL (If applicable) | | 7a. NAME OF MONITORING ORGANIZATION | | | | | | | | | | | | | | | | | | | | | |
| 6c. ADDRESS (City, State, and ZIP Code) Logan, UT 84322-5600 | | | 7b. ADDRESS (City, State, and ZIP Code) | | | | | | | | | | | | | | | | | | | | | | |
| 8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command | | 8b. OFFICE SYMBOL (If applicable) | | 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER Contract No. DAMD17-86-C-6028 | | | | | | | | | | | | | | | | | | | | | |
| 8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21702-5012 | | | 10. SOURCE OF FUNDING NUMBERS | | | | | | | | | | | | | | | | | | | | | | |
| PROGRAM ELEMENT NO. 63763A | | PROJECT NO. 3M2-63763D807 | | TASK NO. AD | WORK UNIT ACCESSION NO. 057 | | | | | | | | | | | | | | | | | | | | |
| 11. TITLE (Include Security Classification) In Vitro and In Vivo Phlebovirus Inhibition by Nucleosides Related to Ribavirin Published in "Nucleosides & Nucleotides, 8(5&6), 1159-1160 (1989)) | | | | | | | | | | | | | | | | | | | | | | | | | |
| 12. PERSONAL AUTHOR(S) John H. Huffman; Robert W. Sidwell; Roland K. Robins; Ganapathi R. Revankar; Dominique Y. Pifar | | | | | | | | | | | | | | | | | | | | | | | | | |
| 13a. TYPE OF REPORT Reprint | | 13b. TIME COVERED FROM _____ TO _____ | | 14. DATE OF REPORT (Year, Month, Day) 1989 | | | | | | | | | | | | | | | | | | | | | |
| 15. PAGE COUNT | | | | | | | | | | | | | | | | | | | | | | | | | |
| 16. SUPPLEMENTARY NOTATION Contract Title: Determination of the In Vitro and In Vivo Activity of Compounds Tested Against Punta Toro Virus | | | | | | | | | | | | | | | | | | | | | | | | | |
| 17. COSATI CODES | | | 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) | | | | | | | | | | | | | | | | | | | | | | |
| FIELD | GROUP | SUB-GROUP | | | | | | | | | | | | | | | | | | | | | | | |
| 06 | 13 | | | | | | | | | | | | | | | | | | | | | | | | |
| 06 | 15 | | | | | | | | | | | | | | | | | | | | | | | | |
| 19. ABSTRACT (Continue on reverse if necessary and identify by block number) | | | | | | | | | | | | | | | | | | | | | | | | | |
| <div style="text-align: center;">  </div> | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td colspan="2">Accession For</td> </tr> <tr> <td>NTIS GRA&I</td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>DTIC TAB</td> <td><input type="checkbox"/></td> </tr> <tr> <td>Unannounced</td> <td><input type="checkbox"/></td> </tr> <tr> <td>Justification</td> <td></td> </tr> <tr> <td colspan="2">By _____</td> </tr> <tr> <td colspan="2">Distribution/</td> </tr> <tr> <td colspan="2">Availability Codes</td> </tr> <tr> <td>Dist</td> <td>Avail and/or Special</td> </tr> <tr> <td>A-1</td> <td>20</td> </tr> </table> | | | | | | Accession For | | NTIS GRA&I | <input checked="" type="checkbox"/> | DTIC TAB | <input type="checkbox"/> | Unannounced | <input type="checkbox"/> | Justification | | By _____ | | Distribution/ | | Availability Codes | | Dist | Avail and/or Special | A-1 | 20 |
| Accession For | | | | | | | | | | | | | | | | | | | | | | | | | |
| NTIS GRA&I | <input checked="" type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | |
| DTIC TAB | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | |
| Unannounced | <input type="checkbox"/> | | | | | | | | | | | | | | | | | | | | | | | | |
| Justification | | | | | | | | | | | | | | | | | | | | | | | | | |
| By _____ | | | | | | | | | | | | | | | | | | | | | | | | | |
| Distribution/ | | | | | | | | | | | | | | | | | | | | | | | | | |
| Availability Codes | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dist | Avail and/or Special | | | | | | | | | | | | | | | | | | | | | | | | |
| A-1 | 20 | | | | | | | | | | | | | | | | | | | | | | | | |
| 20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS | | | 21. ABSTRACT SECURITY CLASSIFICATION | | | | | | | | | | | | | | | | | | | | | | |
| 22a. NAME OF RESPONSIBLE INDIVIDUAL Mrs. Virginia M. Miller | | | 22b. TELEPHONE (Include Area Code) (301) 663-7325 | | 22c. OFFICE SYMBOL SGRD-RMT-S | | | | | | | | | | | | | | | | | | | | |

91 2 05 019

IN VITRO AND IN VIVO PHLEBOVIRUS INHIBITION BY NUCLEOSIDES
RELATED TO RIBAVIRINJohn H. Huffman*, Robert W. Sidwell, Roland K. Robins¹, Ganapathi R.
Revankar¹, and Dominique Y. Pifat²Dept. of Animal, Dairy and Veterinary Sciences, Utah State University,
Logan, UT 84322-5600, ¹ICN Nucleic Acid Research Institute, Costa Mesa,
CA, and ²U.S. Army Medical Research Institute for Infectious Diseases,
Fort Detrick, Frederick, MD

Abstract: Eleven compounds were compared to ribavirin for their
in vitro and in vivo inhibition of Punta Toro virus (PTV), a phlebovirus
in the Bunyaviridae virus family.

Introduction: These studies were done in an attempt to find
compounds which might be used to overcome diseases due to phlebovirus
infections of humans and animals.

Materials and Methods: Virus: The Adames strain of Punta
Toro virus was prepared in cell culture for all experiments.

Cells: Continuous passaged Rhesus monkey kidney cells (LLC-MK₂
Derivative) were grown in Minimum Essential Medium (MEM) with fetal
bovine serum (FBS) and NaHCO₃, without antibiotics. These cells were
used to prepare virus pools and in all virus titrations. Gentamicin (50
µg/ml) was included in medium in which virus was prepared or titered.

Mice: C57BL/6 mice, 3-4 weeks old, were used for in vivo
antiviral evaluations. They were infected by subcutaneous (s.c.)
injection of the PTV preparations.

Compounds: The compounds used in these experiments were provided
by the U.S. Army Medical Research Institute for Infectious Diseases.

Antiviral evaluations: In vitro experiments were evaluated by use
of inhibition of viral cytopathogenic effect in 96-well microplates as
previously described¹. The 50% effective dose (ED₅₀) was determined for
each compound. The 50% cytotoxic dose (CD₅₀) was also determined by
microscopic examination of concomitantly run toxicity controls for cell
anomalies. The therapeutic index (TI) of each compound was calculated

TABLE 1. COMPARATIVE IN VITRO AND IN VIVO ANTIVIRAL ACTIVITY OF 12 COMPOUNDS VS PUNTA TORO VIRUS

| Compound | Number | VR ^a | In vitro TI ^b | In vivo TI ^c |
|--|--------|-----------------|--------------------------|-------------------------|
| thioformycin B | 1 | 1.5 | 175 | 8 |
| ribavirin | 2 | 1.2 | 90 | 14 |
| 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide hydrochloride | 3 | 1.1 | 120 | 32 |
| selenazofurin | 4 | 1.0 | 16 | 8 |
| formycin A | 5 | 0.8 | 8 | 0 |
| tiazofurin | 6 | 0.8 | 2 | 8 |
| ribavirin 2',3',5'-triacetate | 7 | 0.4 | 4 | 32 |
| tiazofurin 2',3',5'-triacetate | 8 | 0.4 | 0.8 | ≥3 |
| 3-deazaguanine | 9 | 0.3 | 5 | 8 |
| formycin B | 10 | 0.3 | 3 | 8 |
| 9-(β-D-ribofuranosyl)purine-6-thiocarboxamide | 11 | 0.2 | 3 | 8 |
| 3-bromo-4-chloropyrazolo-[3,4-d]-pyrimidine | 12 | 0.05 | <1 | 2 |

^aVirus Rating.

^bMaximum TI obtained (TI = CD50 + ED50) (μg/ml).

^cMaximum TI obtained (TI = Maximum Tolerated Dose + Minimum Statistically Effective Dose) (mg/kg/day).

as a measure of antiviral activity (TI = CD50 + ED50). The virus rating (VR) of each compound was also determined¹.

In vivo experiments were evaluated by use of several parameters, but only one (the statistically significant number of survivors 21-days post-virus injection) was utilized in calculations of the TIs shown.

Results and Discussion: The results, sorted by VR, are shown in Table 1. The compounds most active in vivo (2, 3, 6 and 7) were also among the most active compounds seen in vitro with the exception of 7, which had very low in vitro activity. Compound 1 had very low in vivo activity, even though it had the highest in vitro activity. Compounds 2, 3, 6 and 7 were all effective in vivo when given as a single inoculation as late as 48 hr after virus infection.

REFERENCES

1. R.W. Sidwell and J. H. Huffman, *Appl. Microbiol.*, 22, 797 (1971).

Supported by: DAMD-17-86-C-6028, U.S. Army Medical Research Development Command.